|Mr. Antony Mattessich||Pres, CEO & Director||907.55k||N/A||1967|
|Ms. Patricia Kitchen||Chief Operating Officer||639.64k||N/A||1978|
|Dr. Michael H. Goldstein M.M., M.D., M.B.A.||Pres of Ophthalmology & Chief Medical Officer||550.76k||N/A||1967|
|Mr. Donald Notman Jr.||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Peter K. Jarrett Ph.D.||Chief Scientific Officer||N/A||N/A||1957|
|Mr. Philip C. Strassburger||Gen. Counsel||N/A||N/A||N/A|
|Mr. William H. Ransone II||VP of Global Sales & Marketing||N/A||N/A||N/A|
|Mr. Christopher G. White||Sr. VP of Bus. & Corp. Devel.||N/A||N/A||1962|
|Ms. Tracy Smith||VP of HR||N/A||N/A||N/A|
|Mr. Scott Corning||Sr. VP of Commercial||N/A||N/A||N/A|
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Ocular Therapeutix, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 7; Compensation: 10.